THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy (THUNDER2)
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality in locally advanced rectal cancer (LARC) and patients achieving complete response to treatment (CR) usually have a better prognosis in terms of local control (LC), metastases-free survival (MFS) and overall survival (OS).
Recently, an early tumour regression index (ERITCP) was introduced, to predict pathological CR (pCR) after nCRT in LARC patients. In particular, the authors found that the patients with ERITCP <13.1 show a strong response during therapy and have a lower probability to experience distant relapses.
Aim of this clinical trial is to investigate the impact of dose escalation in rectal cancer, identifying the poor responder cases using the ERI index during the course of radiotherapy and increasing the prescribed dose in these patients.
Adopting this boosting protocol, an increase of 10% of CR (clinical and pathological) rate is expected.
For patients enrolled in the trial, chemoradiotherapy (CRT) will be administered using the MRI guided Radiotherapy (MRgRT) machine available in our institution.
If ERI will be inferior than 13.1 the patient will continue the original treatment. Patients with complete clinical response will go through wait and see approach.
If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
The number of cases to be enrolled will be 63. The primary endpoints will be complete response considered as: ypT0N0 in case of Total Mesorectal Excision (TME), ypT0ycN0 in case of LE, ycT0N0 in case of WW; prospective validation of delta radiomics MR-guide Radiotherapy model.
研究概览
地位
详细说明
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality in locally advanced rectal cancer (LARC) and patients achieving complete response to treatment (CR) usually have a better prognosis in terms of local control (LC), metastases-free survival (MFS) and overall survival (OS).
Since response to radiotherapy is dose dependent in rectal cancer, dose escalation may lead to higher complete response rates. The possibility to predict patients who will achieve CR before surgery or during nCRT is of crucial importance. Recently, an early tumour regression index (ERITCP) was introduced, to predict pathological CR (pCR) after nCRT in LARC patients. In particular, the authors found that the patients with ERITCP <13.1 show a strong response during therapy and have a lower probability to experience distant relapses.
Aim of this clinical trial is to investigate the impact of dose escalation in rectal cancer, identifying the poor responder cases using the ERI index during the course of radiotherapy and increasing the prescribed dose in these patients.
Adopting this boosting protocol, an increase of 10% of CR (clinical and pathological) rate is expected.
For patients enrolled in the trial, chemoradiotherapy (CRT) will be administered using the MRI guided Radiotherapy (MRgRT) machine available in our institution.
The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis. Chemotherapy with 5-fluorouracil(5-FU) or oral capecitabine will be administered continuously.
A 0.35 Tesla Magnetic Resonance image will be acquired at simulation and every day during MRgRT. At fraction 10, ERI will be calculated.
If ERI will be inferior than 13.1 the patient will continue the original treatment. Patients with complete clinical response will go through wait and see approach.
If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
After the end of CRT, the clinical response will be evaluated 8-10 weeks using high tesla MR and CT images or FDGPET-CT image 8-10 weeks after the end of nCRT. Surgery will be performed 12-16 weeks after the end of the CRT in case of partial or stable or progression disease, while in case of major or complete clinical response at restaging imaging, a Watch and Wait (W&W) or local excision (LE) approach should be followed. Late toxicity and quality of life (QoL) will be scored at first follow-up (FUP) and at 1 and 2 years of FUP according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 scale, functional scales and QoL questionnaires (LARS and SEXUAL questionnaires, at the start of treatment, after surgery and at 1 and 2 years of FUP), respectively.
The number of cases to be enrolled will be 63: all the patients will be treated at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. All the cases will be discussed in weekly multidisciplinary tumor board to share the best therapeutic options, both at the diagnosis and at presurgical restaging.
. The primary endpoints will be complete response considered as: ypT0N0 in case of Total Mesorectal Excision (TME), ypT0ycN0 in case of LE, ycT0N0 in case of WW; prospective validation of delta radiomics MR-guide Radiotherapy model.
The secondary endpoints will be:3 years LC, MFS, Disease Free Survival (DFS), OS; R0 resection rate; Tumor Regression Grade (TRG) 1, TRG 2, Neoadjuvant Rectal (NAR) score; Sphincter preservation rate; Organ preservation rate; Rectal and sexual functions.
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Giuditta Chiloiro, MD PhD
- 电话号码:+ 39 3934360389
- 邮箱:giuditta.chiloiro@policlinicogemelli.it
学习地点
-
-
-
Roma、意大利、00168
- 招聘中
- Fondazione Policlinico Universitario A.Gemelli IRCCS
-
接触:
- Margherita Zona
- 电话号码:+39 0630156261
- 邮箱:margherita.zona@policlinicogemelli.it
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histological proven adenocarcinoma of the rectum cT2-3, N0-2 or cT4 for anal sphincter involvement N0-2a, M0
- No prior radiotherapy in pelvic region;
- Tumour located between 0 and 15 cm above the anal verge;
- Not mesorectal fascia involvement for tumor
- No extramesorectal nodes involvement
- No extramural venous invasion (EMVI)
- No rectal mucinous adenocarcinoma histology
- No contra-indications for MRI
- Eastern Cooperative Oncology Group (ECOG) 0-1
- Age over 18 years
- Adequate hematological function: granulocyte count > 1500/microl; Hemoglobin level > 10 g/dl; Platelet count > 100000/microl; Alanine Aminotransferase/ aspartate aminotransferase (ALT/AST): 7-45 UI/L;
- No other malignancies in the previous history (except skin and initial cervical cancer);
- Absence of important comorbidities: severe cardiac or coagulative disease, moderate or severe; restrictive/obstructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment.
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
- Absence of pregnancy or lactating female patients;
- Written informed consent
Exclusion Criteria: not defined
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction >13.1
All patients will be treated on MRgRT, at the second week , patients with an ERI > 13.1 will underwent RT dose intensification on GTV + 3 mm to 60.1 Gy with a Simultaneous Integrated Boost (SIB).
|
The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis.
Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously.
A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT.
At fraction 10, ERI will be calculated.
If ERI will be inferior than 13.1 the patient will continue the original treatment.
If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
|
无干预:LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction < 13.1
All patients will be treated on MRgRT, at the second week , patients with an ERI < 13.1 will underwent standard RT dose of 55Gy on tumor and corresponding mesorectum
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Complete response
大体时间:6 months
|
ypT0N0 in case of TME, ypT0ycN0 in case of LE, ycT0N0 in case of WW
|
6 months
|
Prospective validation of delta radiomics MR-guide Radiotherapy model
大体时间:6 months
|
correlation between response prediction and clinical or pathological response
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
3 years Local control
大体时间:3 years follow up
|
survival outcomes
|
3 years follow up
|
3 years Metastasis Free Survival
大体时间:3 years follow up
|
survival outcomes
|
3 years follow up
|
3 years Disease Free Survival
大体时间:3 years follow up
|
survival outcomes
|
3 years follow up
|
3 years Overall Survival
大体时间:3 years follow up
|
survival outcomes
|
3 years follow up
|
R0 resection rate
大体时间:6 months
|
percentage of surgical intervention with negative margins
|
6 months
|
Tumor Regression Grade 2
大体时间:6 months
|
surgical outcomes
|
6 months
|
Neoadjuvant rectal (NAR) score
大体时间:6 months
|
surgical outcomes
|
6 months
|
Tumor Regression Grade 1
大体时间:6 months
|
surgical outcomes
|
6 months
|
Sphincter preservation rate
大体时间:6 months
|
percentage of surgical intervention without the positioning of permanent stomia
|
6 months
|
Organ preservation rate
大体时间:3 years follow up
|
percentage of patients underwent conservative approaches (WW or EL)
|
3 years follow up
|
Rectal function
大体时间:3 years follow up
|
impact of therapy on rectal functions by MSKCC questionnaire (from always to never with 5 items)
|
3 years follow up
|
Sexual function
大体时间:3 years follow up
|
impact of therapy on sexual function by IIEF and FSFI questionnaires (from 1 worst to 5 better)
|
3 years follow up
|
合作者和调查者
合作者
调查人员
- 首席研究员:Giuditta Chiloiro, MD PhD、Fondazione Policlinico Universitario A. Gemelli, IRCCS
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.